J&J to buy Actelion for $30b.
ALLSCHWIL, Switzerland (Reuters) – US health-care giant Johnson & Johnson will buy Swiss biotech company Actelion in a $30 billion allcash deal that includes spinning off Actelion’s research and development pipeline, the companies said on Thursday.
The biggest European drugs takeover in 13 years gives J&J access to the Swiss group’s range of high-price, high-margin medicines for rare diseases, helping it diversify its drug portfolio as its biggest product, Remicade for arthritis, faces cheaper competition.
The offer to pay $280 per share, following weeks of exclusive talks, was unanimously approved by the boards of directors of both companies.
The deal represents a 23% premium to Actelion’s closing price on Wednesday and is more than 80% above the November 23 closing price before reports emerged that Europe’s biggest biotech company had attracted takeover interest.
Actelion shares jumped 20% to 273.30 francs in early afternoon trading as investors welcomed the deal.
“The structure is very attractive,” said Eleanor Taylor Jolidon, a fund manager at Union Bancaire Privee in Geneva, a top-40 Actelion investor.
The price vindicates the strategy of cardiologist JeanPaul Clozel, who cofounded the company with his pediatrician wife, Martine, and friends in 1997 and has fended off bids over the years in the belief he could increase Actelion’s value by keeping it independent.
Jefferies analysts said they did not expect any counterbid or competition concerns. Berenberg analysts called it “a fantastic deal for Actelion and its shareholders” given concerns about the longterm growth prospects for its main products.
Actelion has been the subject of takeover speculation for weeks after J&J launched and then halted discussions with the Swiss company. French drugmaker Sanofi had also been interested, sources said, but was sidelined after J&J returned and began exclusive negotiations in December.
Sanofi’s failure to come away with a big deal for a second time has added to pressure on its management.
Clozel said the J&J offer – putting Actelion’s established drugs into its bigger commercial organization while leaving riskier early-stage R&D assets in the new 600-employee company for Clozel to develop – convinced him this was the right one.
The deal makes the Clozels billionaires.